Tonix Pharmaceuticals Company Insiders
TNXP Stock | USD 28.76 1.01 3.39% |
Tonix Pharmaceuticals employs about 81 people. The company is managed by 13 executives with a total tenure of roughly 189 years, averaging almost 14.0 years of service per executive, having 6.23 employees per reported executive. Discussion of Tonix Pharmaceuticals' management performance can provide insight into the enterprise performance.
Tonix |
Tonix Pharmaceuticals' Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Tonix Pharmaceuticals' future performance. Based on our forecasts, it is anticipated that Tonix will maintain a workforce of slightly above 80 employees by April 2025.Tonix Pharmaceuticals Management Team Effectiveness
The company has return on total asset (ROA) of (0.4407) % which means that it has lost $0.4407 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.3869) %, meaning that it created substantial loss on money invested by shareholders. Tonix Pharmaceuticals' management efficiency ratios could be used to measure how well Tonix Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of 03/27/2025, Return On Tangible Assets is likely to drop to -0.84. In addition to that, Return On Capital Employed is likely to drop to -0.99. At this time, Tonix Pharmaceuticals' Total Current Liabilities is relatively stable compared to the past year. As of 03/27/2025, Liabilities And Stockholders Equity is likely to grow to about 171 M, while Non Current Liabilities Total is likely to drop slightly above 3 M.As of 03/27/2025, Common Stock Shares Outstanding is likely to grow to about 773.2 K, though Net Loss is likely to grow to (99.9 M).
Tonix Pharmaceuticals Workforce Comparison
Tonix Pharmaceuticals Holding is rated fifth in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 1,561. Tonix Pharmaceuticals holds roughly 81.0 in number of employees claiming about 5% of equities under Health Care industry.
Tonix Pharmaceuticals Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Tonix Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Tonix Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Tonix Pharmaceuticals insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
---|---|---|---|---|---|
2025-03-01 | 1.1111 | 10 | 9 | 443,116 | 8.59 |
2024-06-01 | 7.0 | 7 | 1 | 732,347 | 0.81 |
2023-03-01 | 9.0 | 9 | 1 | 2,738,000 | 83,000 |
2021-09-01 | 2.0 | 2 | 1 | 249,437 | 237,437 |
2021-06-01 | 8.0 | 8 | 1 | 1,901,174 | 68,750 |
2020-06-01 | 15.0 | 15 | 1 | 6,996,250 | 30,000 |
2019-06-01 | 16.0 | 16 | 1 | 716,360 | 0.00 |
2019-03-01 | 11.0 | 11 | 1 | 122,720 | 10,000 |
2018-09-01 | 1.0 | 1 | 1 | 15,000 | 15,000 |
2018-06-01 | 19.0 | 19 | 1 | 213,100 | 7,000 |
2018-03-01 | 5.5 | 11 | 2 | 605,003 | 19,000 |
2017-12-01 | 0.1667 | 1 | 6 | 5,300 | 36,967 |
2017-09-01 | 2.0 | 2 | 1 | 20,000 | 20,000 |
2017-06-01 | 16.0 | 16 | 1 | 184,875 | 6,105 |
2017-03-01 | 3.0 | 9 | 3 | 287,375 | 18,000 |
2016-03-01 | 1.9 | 19 | 10 | 342,850 | 32,050 |
2015-06-01 | 0.25 | 1 | 4 | 4,500 | 23,150 |
2015-03-01 | 17.0 | 34 | 2 | 443,143 | 6,600 |
2014-12-01 | 7.0 | 14 | 2 | 307,530 | 33,530 |
2014-09-01 | 1.0 | 2 | 2 | 17,059 | 17,059 |
2014-06-01 | 6.0 | 12 | 2 | 255,000 | 0.00 |
2013-06-01 | 2.4286 | 17 | 7 | 768,568 | 766,668 |
2013-03-01 | 1.0 | 10 | 10 | 4,530,000 | 0.00 |
Tonix Pharmaceuticals Notable Stakeholders
A Tonix Pharmaceuticals stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Tonix Pharmaceuticals often face trade-offs trying to please all of them. Tonix Pharmaceuticals' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Tonix Pharmaceuticals' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Bradley CPA | CFO Treasurer | Profile | |
M Morris | Acting CFO and Chief Admin. Officer | Profile | |
Seth MD | President, CoFounder | Profile | |
CPA CPA | CFO Treasurer | Profile | |
Daniel MD | Consultant | Profile | |
Dr MBA | Executive Research | Profile | |
Thomas MBA | Executive Operations | Profile | |
Sina Bavari | Executive Development | Profile | |
Thomas Englese | Executive Operations | Profile | |
James MBA | Executive Operations | Profile | |
Gregory MD | Chief Secretary | Profile | |
Darryl Rideout | Executive Chemistry | Profile | |
MPH MD | Executive Medical | Profile |
About Tonix Pharmaceuticals Management Performance
The success or failure of an entity such as Tonix Pharmaceuticals often depends on how effective the management is. Tonix Pharmaceuticals management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Tonix management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Tonix management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.80) | (0.84) | |
Return On Capital Employed | (0.95) | (0.99) | |
Return On Assets | (0.80) | (0.84) | |
Return On Equity | (0.93) | (0.98) |
Tonix Pharmaceuticals Workforce Analysis
Traditionally, organizations such as Tonix Pharmaceuticals use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Tonix Pharmaceuticals within its industry.Tonix Pharmaceuticals Manpower Efficiency
Return on Tonix Pharmaceuticals Manpower
Revenue Per Employee | 124.6K | |
Revenue Per Executive | 776.5K | |
Net Loss Per Employee | 1.6M | |
Net Loss Per Executive | 10M | |
Working Capital Per Employee | 1.2M | |
Working Capital Per Executive | 7.7M |
Additional Tools for Tonix Stock Analysis
When running Tonix Pharmaceuticals' price analysis, check to measure Tonix Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tonix Pharmaceuticals is operating at the current time. Most of Tonix Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Tonix Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tonix Pharmaceuticals' price. Additionally, you may evaluate how the addition of Tonix Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.